2268.HK

Contract drug services provider WuXi XDC Cayman Inc. (2268.HK) on Wednesday said its revenue grew by over 60% in the first half of 2025, while its adjusted net profit surged by more than 67%. The company added its net profit grew by more than 50% during the period, which would equal 740 million yuan or more based on its 490 million yuan ($68 million) profit in the year-ago period.

This strong growth owed largely to strong downstream demand from makers of antibody-drug conjugates (ADCs); the company’s leadership in the bioconjugate drug services market; and the rapid ramp-up of its newly commissioned production lines.

Shares of WuXi rose 8.6% to HK$53.65 on Wednesday. The stock is up 73% this year.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, clickhere

Recent Articles

Losses continue to widen and debts continue to pile up, Vanke not yet out of the woods

Vanke not out of the woods as losses, debt keep mounting

Despite being taken over by Shenzhen Metro Group and promised full financial support, the developer, while avoiding defaults, reported its loss widened in the first half of 2025 Key Takeaways:…
Mininglamp makes marketing software

Mininglamp IPO advances with key regulatory approval

China’s securities regulator has registered the leading marketing software maker’s Hong Kong listing, which could raise more than $100 million Key Takeaways: Mininglamp’s Hong Kong IPO has been approved by…